Merck announces exceptional hepatitis C therapy study results

Merck releases hepatitis C therapy phase 2/3 study results
Merck releases hepatitis C therapy phase 2/3 study results | Courtesy of mercknewsroom.com
Merck recently released the results from its Phase 2 and 3 study of an investigational therapy, grazoprevir/elbasvir, for patients with chronic hepatitis C infections and advanced chronic kidney disease.

The treatment regimen of 100mg of grazoprevir and 50 mg of elbasvir requires daily doses. The study involved treatment-naïve patients as well as other patients who did not succeed with prior pegylated interferon HCV therapy. All of the patients enrolled in the study had CKD in Stage 4 or 5.

Twelve weeks after finishing the treatments, 115 of the 116 patients (or 99 percent) showed sustained virologic responses.

“There is an unmet medical need to treat chronic hepatitis C virus infection in patients with advanced chronic kidney disease,” Houston Methodist Hospital Chief of Hepatology Howard Monsour said. “In this trial, the first to investigate an all-oral ribavirin-free treatment regimen in treatment-naïve and treatment-experienced CKD patients, treatment with grazoprevir and elbasvir for 12 weeks was effective in this study population with HCV genotype 1 infection.”

Merck officials have presented this material at The International Liver Congress 2015, which is part of the 50th annual congress of the European Association for the Study of the Liver.

Organizations in this Story

Houston Methodist Hospital

Want to get notified whenever we write about Houston Methodist Hospital ?
Next time we write about Houston Methodist Hospital, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.